Skip to main content

Cancer

30
Oct 2025

National development projects for precision diagnostics of solid tumors in Sweden

On October 20, 2025, Genomic Medicine Sweden (GMS) announced the launch of five strategic development projects aimed at extending access to advanced diagnostics nationwide. The projects will focus on updating national GMS gene panel (big NGS panel for solid tumors), liquid biopsies, cell-free tumor DNA (ctDNA) for diagnosis and follow-up of metastatic breast cancer, gene panels for hepatopancreatobiliary (HPB) cancer, and improving diagnosis of sarcoma.
16
Oct 2025

Technologies prioritized for evaluation within the National HTA Program in 2025 in Italy

On October 14, 2025, the National Agency for Regional Health Services (AGENAS) published the list of technologies prioritized for evaluation within the National HTA Program for Medical Devices in 2025. Technologies from the fields of endocrinology, men’s health, neurology/neurosurgery, and radiotherapy have been identified as priorities and are currently undergoing health technology assessment.
18
Aug 2025

August 2025 update of the Catalog of Genetic and Genomic Tests in Spain

In August 2025, the Common Catalog of Genetic and Genomic Tests of the National Health System in Spain was updated. Two sections with a total of 140 new genetic tests were introduced: one for bone diseases, including craniofacial anomalies, and another for kidney diseases and urogenital disorders. Furthermore, six new tests were added in pediatric oncohematology. Other changes concerned adult oncohaematology, hereditary metabolic, and mitochondrial diseases.
21
Jul 2025

Pre-launch adjustments were requested to the new outpatient tariff system in Switzerland

The new Swiss outpatient billing system, comprising the TARDOC catalog of individual service tariffs and outpatient flat rates, approved by the Federal Council, is expected to take effect on January 1, 2026. On July 15, 2025, the Organization for Outpatient Physician Tariffs (OAAT AG) requested pre-launch adjustments to this system concerning hospital emergency and non-physician services, combination therapy in cancer treatment, wound care, and pathology services.
03
Jul 2025

Coverage positions published by the Dutch Healthcare Institute in Q1-Q2 2025

In the first and second quarters of 2025, the Dutch Healthcare Institute (ZIN) published three coverage positions concerning the ENT, gastrointestinal, and in-vitro diagnostic fields. Two of the three decisions (Internal nasal valve correction for airway blockage and molecular diagnostics of the NTRK gene fusion in cancer patients) received favorable recommendations for coverage under basic health insurance.